Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NexoBrid versus standard of care in hospitalized children with thermal burns
NL-OMON45033Phase 3Active, not recruiting
- Sponsor
- MediWound
- Start
- Apr 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in thermal injury and burn injury comparing NexoBrid with Standard of care (2 arms). Primary endpoints: Earlier eschar removal, Reduction in surgical needs and 1 more. Started Apr 2017; status: active, not recruiting.
02
Drugs
bromelain
03
Conditions
thermal injuryburn injury
Beyond the preview
Go deeper on NL-OMON45033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45033.